SYMBIOTEC PHARMALAB LTD (SYMBIOTEC) financials

SYMBIOTEC PHARMALAB LTD (SYMBIOTEC) NSE/BSE financials on Fincrux: quarterly results, profit and loss, cash flow, balance sheet, ratios, and shareholding.

Symbiotec is a research-driven, science-based pharmaceutical and biotechnology company with a strong global leadership position in Corticosteroid and SteroidalHormone Active Pharmaceutical Ingredients (APIs). It has evolved from a Lab-ScaleSteroid manufacturer into a fully integrated global platform.[1]

Market Cap: ₹7,074Cr.
Current Price: ₹1,101
Stock P/E: 44.6
ROE: 17.1%
ROCE: 21.4%
Book Value: ₹
Dividend Yield: 0.00%
52W High / Low: ₹1,246/934

In Jun 2026, SYMBIOTEC PHARMALAB LTD (SYMBIOTEC) reported sales ₹211 Cr and net profit ₹47 Cr.

Annual Mar 2026: sales ₹845 Cr, net profit ₹116 Cr.

Shareholding: Promoters 33.28% (Sep 2026), FIIs 21.08% (Sep 2026), DIIs 27.51% (Sep 2026), Public 18.12% (Sep 2026), No. of Shareholders 4,27,730% (Sep 2026).

SYMBIOTEC quarterly results (₹ Cr.)
Category	Jun 2025	Mar 2026	Jun 2026
Sales	204	213	211
Expenses	142	164	152
Operating Profit	62	49	59
OPM %	31%	23%	28%
Other Income	11	-34	20
Interest	5	6	6
Depreciation	9	11	10
Profit before tax	59	-3	63
Tax %	25%	430%	25%
Net Profit	45	-16	47
EPS in Rs	69.90	-2.50	7.49
Raw PDF	—	—	—

SYMBIOTEC profit and loss (₹ Cr.)
Category	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Sales	623	634	564	674	757	845
Expenses	420	529	483	531	538	605
Operating Profit	202	105	80	143	219	241
OPM %	32%	17%	14%	21%	29%	28%
Other Income	9	6	-52	20	32	-4
Interest	7	3	8	8	17	24
Depreciation	22	25	28	37	38	39
Profit before tax	183	83	-8	118	196	173
Tax %	26%	25%	191%	25%	26%	33%
Net Profit	136	62	-23	89	146	116
EPS in Rs	123.95	56.44	-20.72	81.33	229.01	18.46
Dividend Payout %	0%	0%	0%	0%	0%	0%

SYMBIOTEC balance sheet (₹ Cr.)
Category	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Equity Capital	11	11	11	11	11	—
Reserves	622	684	662	750	900	—
Borrowings	47	64	107	52	293	—
Other Liabilities	161	136	135	274	145	—
Total Liabilities	842	894	915	1,087	1,348	—
Fixed Assets	248	266	266	324	317	—
CWIP	27	23	74	19	59	—
Investments	123	130	66	42	44	—
Other Assets	445	476	510	702	928	—
Total Assets	842	894	915	1,087	1,348	—

SYMBIOTEC cash flows (₹ Cr.)
Category	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Cash from Operating Activity	158	24	93	147	83	—
Cash from Investing Activity	-79	-34	-132	-81	-292	—
Cash from Financing Activity	-79	15	37	-63	225	—
Net Cash Flow	-0	4	-3	4	16	—
Free Cash Flow	116	-18	22	107	8	—
CFO/OP	99%	45%	136%	128%	54%	—

SYMBIOTEC shareholding pattern (%)
Category	Sep 2026
Promoters	33.28%
FIIs	21.08%
DIIs	27.51%
Public	18.12%
No. of Shareholders	4,27,730

SYMBIOTEC key ratios
Category	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Debtor Days	70	83	73	68	85	—
Inventory Days	309	250	304	378	309	—
Days Payable	151	86	109	254	101	—
Cash Conversion Cycle	228	246	268	191	293	—
Working Capital Days	111	137	110	105	53	—
ROCE %	—	12%	8%	16%	21%	—

SYMBIOTECUpdated 13 Oct 2026, 1:31

Symbiotec Pharmalab Ltd

SYMBIOTECUpdated 13 Oct 2026, 1:31

Market Cap

₹7,074Cr.

Current Price

₹1,101

High / Low

₹1,246/934

Stock P/E

44.6

ROE17.1%

ROCE21.4%

Book Value₹

Face Value₹2.00

Dividend Yield0.00%

About

Quarterly results

Last reported quarters₹ Cr.

Quarter	Sales	Interest	Expenses	Other Income	Depreciation	Profit Before Tax	Tax	Net Profit	EPS (₹)
Jun 2025	204	5	142	11	9	59	25	45	69.9
Mar 2026	213	6	164	-34	11	-3	430	-16	-2.5
Jun 2026	211	6	152	20	10	63	25	47	7.49

Profit & loss

Annual statement₹ Cr.

Year	Sales	Interest	Expenses	Other Income	Depreciation	Profit Before Tax	Tax	Net Profit	EPS (₹)
Mar 2021	623	7	420	9	22	183	26	136	123.95
Mar 2022	634	3	529	6	25	83	25	62	56.44
Mar 2023	564	8	483	-52	28	-8	191	-23	-20.72
Mar 2024	674	8	531	20	37	118	25	89	81.33
Mar 2025	757	17	538	32	38	196	26	146	229.01
Mar 2026	845	24	605	-4	39	173	33	116	18.46

Shareholding pattern

As of Sep 2026%

Shareholding trend

Ownership over time%

Quarter	Promoters	FIIs	DIIs	Public
Sep 2026	33.28%	21.08%	27.51%	18.12%

Balance sheet

Assets & liabilities₹ Cr.

Period	Equity Capital	Reserves	Borrowings	Other Liabilities	Total Liabilities	Fixed Assets	CWIP	Investments	Other Assets	Total Assets
Mar 2021	11	622	47	161	842	248	27	123	445	842
Mar 2022	11	684	64	136	894	266	23	130	476	894
Mar 2023	11	662	107	135	915	266	74	66	510	915
Mar 2024	11	750	52	274	1087	324	19	42	702	1087
Mar 2025	11	900	293	145	1348	317	59	44	928	1348
Mar 2026	—	—	—	—	—	—	—	—	—	—

Cash flows

Operating, investing & financing₹ Cr.

Period	Operating	Investing	Financing	Net cash flow
Mar 2021	158	-79	-79	0
Mar 2022	24	-34	15	4
Mar 2023	93	-132	37	-3
Mar 2024	147	-81	-63	4
Mar 2025	83	-292	225	16
Mar 2026	—	—	—	—

Key ratios

Historical financial ratios

Category	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Debtor Days	70	83	73	68	85	—
Inventory Days	309	250	304	378	309	—
Days Payable	151	86	109	254	101	—
Cash Conversion Cycle	228	246	268	191	293	—
Working Capital Days	111	137	110	105	53	—
ROCE %	—	12%	8%	16%	21%	—

Frequently asked questions

Quick answers about this company's financials on Fincrux

What is the market cap of SYMBIOTEC PHARMALAB LTD (SYMBIOTEC)?

The reported market capitalisation for SYMBIOTEC PHARMALAB LTD (SYMBIOTEC) is ₹7,074Cr. on Fincrux. Figures may update with market data and filings.

What is the current share price of SYMBIOTEC?

The current price shown for SYMBIOTEC PHARMALAB LTD (SYMBIOTEC) on Fincrux is ₹1,101 with a 52-week high/low of ₹1,246/934.

What is the P/E ratio of SYMBIOTEC PHARMALAB LTD (SYMBIOTEC)?

The stock P/E for SYMBIOTEC PHARMALAB LTD (SYMBIOTEC) is 44.6 on Fincrux, with ROE at 17.1% and ROCE at 21.4%.

What were SYMBIOTEC latest quarterly results?

For Jun 2026, SYMBIOTEC PHARMALAB LTD (SYMBIOTEC) reported sales ₹211 Cr and net profit ₹47 Cr (figures in ₹ crore unless noted).

What are SYMBIOTEC annual sales and net profit?

For Mar 2026, SYMBIOTEC PHARMALAB LTD (SYMBIOTEC) shows sales of ₹845 Cr and net profit of ₹116 Cr on the Fincrux profit & loss statement.

Who owns SYMBIOTEC PHARMALAB LTD (SYMBIOTEC)?

Latest shareholding for SYMBIOTEC PHARMALAB LTD (SYMBIOTEC) on Fincrux: Promoters 33.28% (Sep 2026), FIIs 21.08% (Sep 2026), DIIs 27.51% (Sep 2026), Public 18.12% (Sep 2026), No. of Shareholders 4,27,730% (Sep 2026).

Where can I find SYMBIOTEC PHARMALAB LTD (SYMBIOTEC) financials?

SYMBIOTEC PHARMALAB LTD (SYMBIOTEC) financials on Fincrux include quarterly results, profit and loss, cash flow, balance sheet, key ratios, and shareholding patterns for NSE/BSE research.

Does Fincrux show SYMBIOTEC balance sheet and cash flow?

Yes. The SYMBIOTEC PHARMALAB LTD (SYMBIOTEC) page on Fincrux includes balance sheet, cash flow statements, historical ratios, and ownership trends alongside quarterly and annual results.

Figures in ₹ crore unless noted. Data sourced for research and may lag filings.

Last updated 13 October 2026 at 1:31